Utility Analyses of AVITI Sequencing Chemistry

Silvia Liu,Carolyn Obert,Yanping Yu,Junhua Zhao,Baoguo Ren,Jia-Jun Liu,Kelly Wiseman,Benjamin J Krajacich,Wenjia Wang,Kyle Metcalfe,Mat Smith,Tuval Ben-Yehezkel,Jianhua Luo

DOI: https://doi.org/10.1101/2024.04.18.590136

2024-06-27

Abstract:Background: DNA sequencing is a critical tool in modern biology. Over the last two decades, it has been revolutionized by the advent of massively parallel sequencing, leading to significant advances in the genome and transcriptome sequencing of various organisms. Nevertheless, challenges with accuracy, lack of competitive options and prohibitive costs associated with high throughput parallel short-read sequencing persist. Results: Here, we conduct a comparative analysis using matched DNA and RNA short-reads assays between Element Biosciences AVITI and Illumina NextSeq 550 chemistries. Similar comparisons were evaluated for synthetic long-read sequencing for RNA and targeted single-cell transcripts between the AVITI and Illumina NovaSeq 6000. For both DNA and RNA short-read applications, the study found that the AVITI produced significantly higher per sequence quality scores. For PCR-free DNA libraries, we observed an average 89.7% lower experimentally determined error rate when using the AVITI chemistry, compared to the NextSeq 550. For short-read RNA quantification, AVITI platform had an average of 32.5% lower error rate than that for NextSeq 550. With regards to synthetic long-read mRNA and targeted synthetic long read single cell mRNA sequencing, both platforms respective chemistries performed comparably in quantification of genes and isoforms. The AVITI displayed a marginally lower error rate for long reads, with fewer chemistry-specific errors and a higher mutation detection rate. Conclusion: These results point to the potential of the AVITI platform as a competitive candidate in high-throughput short read sequencing analyses when juxtaposed with the Illumina NextSeq 550.

Genomics

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to evaluate the performance of Element Biosciences' AVITI sequencing platform in high - throughput short - read - length sequencing and compare it with Illumina's NextSeq 550 sequencing platform. Specifically, the paper focuses on the following aspects:

1. **Sequencing quality**:
- Compare the sequence quality scores (Q - score) of AVITI and NextSeq 550 in short - read - length sequencing, especially their performance in high - precision sequencing (such as Q40).
- Analyze the error rates of the two platforms in PCR - free DNA library and mRNA library sequencing.

2. **Synthetic long - read - length sequencing**:
- Compare the performance of AVITI and Illumina's NovaSeq 6000 in synthetic long - read - length RNA sequencing, especially the accuracy in gene and isoform quantification.
- Evaluate the error rates of the two platforms in long - read - length sequencing, including base substitution and insertion/deletion errors.

3. **Single - cell synthetic long - read - length sequencing**:
- Evaluate the performance of AVITI in single - cell synthetic long - read - length sequencing, especially its application in liver cancer patient samples.
- Compare the performance of AVITI and NovaSeq 6000 in single - cell gene expression and mutation detection.

### Main findings

1. **Short - read - length sequencing**:
- AVITI shows a significantly higher sequence quality score in PCR - free DNA library sequencing, and its average error rate is 89.7% lower than that of NextSeq 550.
- In mRNA library sequencing, the error rate of AVITI is also 32.5% lower than that of NextSeq 550.

2. **Synthetic long - read - length sequencing**:
- For synthetic long - read - length RNA sequencing, AVITI and NovaSeq 6000 show similar performance in gene and isoform quantification, but AVITI has a slightly lower error rate, especially in base substitution and insertion/deletion errors.

3. **Single - cell synthetic long - read - length sequencing**:
- AVITI shows performance comparable to NovaSeq 6000 in single - cell synthetic long - read - length sequencing, especially in gene expression and mutation detection.
- AVITI has higher accuracy in mutation detection and can identify more valid mutations.

### Conclusion

These results indicate that the AVITI platform has performance comparable to or even better than Illumina NextSeq 550 in high - throughput short - read - length sequencing analysis, especially in sequencing quality and error rate. This makes AVITI a potential competitor and can provide a more competitive option in the high - throughput sequencing field.